Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service

Australian and New Zealand Journal of Psychiatry

Volumn 38, Issue 11-12, 2004, Pages 915-922

  Reinders, Jonathan ^a   Parsonage, William ^b   Lange, Diana ^a   Potter, Julia M ^c   Plever, Sally ^a  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Adverse effects; Cardiomyopathy; Clozapine; Myocarditis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT;

AUSTRALIA; CARDIOMYOPATHY; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSENSUS; DIZZINESS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SURVEILLANCE PROGRAM; DYSPNEA; EDEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEALTH CARE FACILITY; HEALTH CARE MANAGEMENT; HEALTH SURVEY; HEART ARRHYTHMIA; HEART DISEASE; HEART MUSCLE BIOPSY; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; MALAISE; MEDICAL STAFF; MENTAL HEALTH SERVICE; MYALGIA; MYOCARDITIS; PERICARDITIS; PSYCHIATRY; REVIEW; SCHIZOPHRENIA; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; AUSTRALIA; CARDIOMYOPATHIES; CLOZAPINE; FEMALE; HOSPITALS, URBAN; HUMANS; INCIDENCE; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; MYOCARDITIS; PSYCHIATRIC DEPARTMENT, HOSPITAL; PSYCHOTIC DISORDERS; RADIOGRAPHY, THORACIC;

EID: 11144267254     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1614.2004.01481.x     Document Type: Review

References (39)

1. Dukes MNG. The importance of adverse reactions in drug regulation. Drug Safety 1990; 5:3-6.
2. Coulter DM, Bate A, Meyboom RHB, Lindquist M, Edwards IR. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001; 322:1207-1209.
3. Hagg S, Spigset O, Bate A, Soderstrom TG. Myocarditis related to clozapine treatment. Journal of Clinical Psychopharmacology 2001; 21:382-388.
4. Grenade LL, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. New England Journal of Medicine 2001; 345:224.
5. Committee on Safety in Medicines. Myocarditis with antipsychotics: recent cases with clozapine. Current Problems in Pharmacovigilance 1993; 19:9-10.
6. Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354:1841-1845.
7. Catalano G, Catalano MC, Wetter RLF. Clozapine induced polyserositis. Clinical Neuropharmacology 1997; 20:352-356.
8. Daly JM, Goldberg RJ, Braman SS. Polyserositis associated with clozapine treatment. American Journal of Psychiatry 1992; 149:1274-1275.
9. Kay SE, Doery J, Sholl D. Clozapine associated pericarditis and elevated yroponin I. Australian and New Zealand Journal of Psychiatry 2002; 36:143-144.
10. Murko A, Clarke S, Black DW. Clozapine and pericarditis with pericardial effusion. American Journal of Psychiatry 2002; 159:494.
11. Phan KLD, Taylor SF. Clozapine-associated cardiomyopathy. Psychosomatics 2002; 43:248.
12. Povlsen UJ, Noring U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine. Acta Psychiatrica Scandinavica 1985; 71:176-185.
13. Ketch J, Herd A, Ludwig L. ST segment elevations without myocardial infarction in a patient on clozapine. American Journal of Emergency Medicine 1996; 14:111-112.
14. Tie H, Walker BD, Singleton CB, Burstill JA, Wyse KR. Clozapine and sudden death. Journal of Clinical Psychopharmacology 2001; 21:630-631.
15. Varma S, Achan K. Dysrhythmia associated with clozapine. Australian and New Zealand Journal of Psychiatry 1999; 33:118-119.
16. Low RA, Fuller MA, Popli A. Clozapine induced atrial fibrillation. Journal of Clinical Psychopharmacology 1998; 18:170-171.
17. Koren W, Kreis Y, Duchowiczny K et al. Lactic acidosis and fatal myocardial failure due to clozapine. Annals of Pharmacotherapy 1997; 31:168-170.
18. Reznik I, Volchek L, Mester R et al. Myotoxicity and neurotoxicity during clozapine treatment. Clinical Neuropharmacology 2000; 23:276-280.
19. Agelink MW, Majewski T, Wurthmann C et al. Effects of newer atypical antipsychotics on autonomic neurocardiac function. A comparison between amisulpride, olanzapine, sertindole, and clozapine. Journal of Clinical Psychopharmacology 2001; 21:8-13.
20. Cohen H, Loewnthal U, Matar M, Kotler M. Association of autonomic dysfunction and clozapine. British Journal of Psychiatry 2001; 179:167-171.
21. Koren W, Koren E, Nacasch N, Ehrenfeld M, Gur H. Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes. Clinical Neuropharmacology 1998; 21:262-264.
22. Meltzer HY, Cola PA, Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 1996; 15:395-405.
23. Maes M, Bosmans E, Kenis G, de Jong R, Smith RS, Meltzer HY. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophrenia Research 1997; 26:221-225.
24. Song C, Lin A, Kenis G, Bosmans E, Maes M. Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophrenia Research 2000; 42:157-164.
25. Hinze-Selch D, Becker EW, Stein GM et al. Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology 1998; 19:114-122.
26. Bandelow B, Degner D, Kreusch U, Ruther E. Myocarditis under therapy with clozapine. Schizophrenia Research 1995; 17:293-294.
27. Kirpekar VC, Deshpande SM, Joshi PP. Reversible myocarditis in a patient receiving clozapine. Indian Heart Journal 2001; 53:779-781.
28. Novartis Pharmaceuticals Canada. Association of clozaril (clozapine) with cardiovascular toxicity [Dear Healthcare Professional letter]. Dorval, QC: Novartis Pharmaceuticals Canada, 2003. Available at: http://www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/advisory/ industry/clozaril_e.html (accessed 23 February 2003).
29. Leo RJ, Kreeger JL, Kim KY. Cardiomyopathy associated with clozapine. Annals of Pharmacotherapy 1996; 30:603-605.
30. Hoehns JD, Fouts MM, Kelly MW, Tu KB. Sudden cardiac death with clozapine and sertraline combination. Annals of Pharmacotherapy 2001; 35:862-866.
31. Wooltorton E. Antipsychotic clozapine (Clozaril); myocarditis and cardiovascular toxicity. Canadian Medical Association Journal 2002; 166:1185-1186.
32. Burke AP, Saenger J, Mullick F, Virmani R. Hypersensitivity myocarditis. Archives of Pathological and Laboratory Medicine 1991; 115:764-769.
33. Fenoglio JJ, McAllister HA, Mullick FG. Drug related myocarditis - hypersensitivity myocarditis. Human Pathology 1981; 12:900-907.
34. Reid P, McArthur M, Pridmore S. Clozapine rechallenge after myocarditis. Australian and New Zealand Journal of Psychiatry 2001; 35:249.
35. Cooper LT. Myocarditis. In: Murphy JG, ed. Mayo Clinic cardiology review. 2nd edn. Philadelphia: Lippincott, Williams & Wilkins, 2000.
36. Hahn EA, Hartz VL, Moon TE et al. The Myocarditis Treatment Trial: design, methods and patient enrolment. European Heart Journal 1995; 16:162-167.
37. Mason JW, O'Connell JB, Herskowitz A et al. A clinical trial of immunosuppressive therapy for myocarditis. New England Journal of Medicine 1995; 333:269-275.
38. Caforio ALP, McKenna WJ. Recognition and optimum management of myocarditis. Drugs 1996; 52:515-525.
39. Lapierre YD, Ghadirian A, St. Laurent J, Chaudhry RP. Clozapine in acute schizophrenia - efficacy and toxicity. Current Therapeutic Research 1980; 27:391-400.